InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.13
(
0.97%
)
US TECH 100
19,572.00
(
0.00%
)
Dow Jones
42,080.37
(
0.30%
)
Brent Oil
77.72
(
0.48%
)
Bitcoin
62,193.47
(
0.10%
)
Post# of 253309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: BTH post# 169573

Thursday, 11/07/2013 5:51:34 PM

Thursday, November 07, 2013 5:51:34 PM

Post# of 253309
Not necessarily. MPNs are complex. As far as I can tell based on the limited data, no one drug can take care of ALL. In that regard, Imetelstat might not be a competitor for JAK inhibitors, rather complement each other in some way, like Revlimid and Velcade in MM. That's my initial take, have to see more data from Imetelstat, JAK1, JAK2.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up